SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ron who wrote (1040)2/25/2000 8:50:00 PM
From: Rick Strange  Read Replies (1) of 1386
 
Don't you think that PARS has signaled how Cohort III of the Phase II hu-211 trial will read? Seems to me that those that have had a look-see at the results, PARS management, are saying with these recent rounds of funding that "we are prepared to go it alone." This is a major shift in philosophy from a company that has always stressed shared and limited risk. On the other hand, if a joint venture offer should come along, PARS is in a much stronger position. I like either alternative.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News